Global CROs market multi-phase execution, while specialists concentrate on specific indications or delivery settings. Every figure below keeps its stated scope restriction—such as office counts versus active clinical sites, overlapping percentages, and ICON’s Accellacare in-home restriction.
IQVIA
Phase claim: Phase IIb/III Trials (Vendor service page claim; this title establishes a marketed Phase IIb/III offering only, not study-specific experience, performance or suitability.)
Therapeutic focus: Includes oncology/hematology, CNS, rare disease, obesity and cell/gene therapy. Company-wide claim; ask for matching study references and a named available team. Source & date
Offices, labs & site footprint: Office/site footprint not quantified on reviewed page
ICON plc
Phase claim: Phase 2–3 clinical operations Company-wide claim; ask for matching study references and a named available team. Source & date
Therapeutic focus: Cardio-metabolic, oncology/hematology, infection, neurology/psychiatry, rare disease, respiratory and biosimilars. Company-wide claim; ask for matching study references and a named available team. Source & date
Offices, labs & site footprint: Office/site footprint not quantified on reviewed page
Medpace
Phase claim: all phases of development (including wholly-owned Phase I Unit) (Vendor homepage claim; does not establish indication-specific trial counts or study outcomes.)
Therapeutic focus: Includes oncology/hematology, endocrine/metabolic, neuroscience, immunology and rare disease. Company-wide claim; ask for matching study references and a named available team. Source & date
Offices, labs & site footprint: Cincinnati, Ohio US headquarters; 33 offices across 46 countries (6,600 employees) (Company-reported headcount/office footprint; does not establish active clinical trial sites in a therapeutic area.)
Parexel
Phase claim: Phase IIb-IV clinical trials (Vendor service page claim; does not establish study-specific experience or team assignments.)
Therapeutic focus: General medicine, infectious disease and vaccines, immunology, neuroscience (Vendor-listed therapeutic areas on integrated clinical development page; additional therapeutic areas may appear on separate pages.)
Offices, labs & site footprint: Raleigh, North Carolina US address listed (US office address on service page; global site reach depends on Site Alliance Network.)
Syneos Health
Phase claim: all phases including Early Phase, Phase II-IV and Real World Evidence (Vendor capability claim; does not establish study-specific outcomes.)
Therapeutic focus: oncology and hematology, neuroscience, rare disease, dermatology (Vendor claim; self-reported ~70% biotech customer portfolio.)
Offices, labs & site footprint: Office/site footprint not quantified on reviewed page
Fortrea
Phase claim: Not stated on reviewed page
Therapeutic focus: Not enumerated on reviewed page
Offices, labs & site footprint: 15,000+ investigators and 5,500+ sites in global network (counts not broken out by US vs ex-US) (Company-reported global site/investigator network; US share not separated on page.)
Thermo Fisher Scientific, PPD clinical services
Phase claim: early development, all phases of clinical development, peri- and post-approval (Vendor brand overview claim across multiple therapeutic areas.)
Therapeutic focus: Not enumerated on reviewed page
Offices, labs & site footprint: Office/site footprint not quantified on reviewed page
Labcorp Drug Development
Phase claim: Not stated on reviewed page
Therapeutic focus: Not enumerated on reviewed page
Offices, labs & site footprint: Madison, Wisconsin and Indianapolis, Indiana flagship US labs plus specialty US labs (US laboratory locations; does not establish clinical trial site operations.)
Worldwide Clinical Trials
Phase claim: Phase I-IIa, Phase II-IV (specializing in Phase IIb-IV peri-approval), RWE, and Transition Studies (Vendor capability claim; specific therapeutic indications sit on separate subpages.)
Therapeutic focus: Not enumerated on reviewed page
Offices, labs & site footprint: Office/site footprint not quantified on reviewed page
Precision for Medicine
Phase claim: Early Phase (first-in-human through Phase 2a) and Late Phase (Phase 2b-4 pivotal) (Vendor capability claim.)
Therapeutic focus: Oncology & immuno-oncology (stated 76% of trials), rare & orphan diseases (stated 67% of trials), autoimmune, cell/gene therapy (Vendor self-reported trial percentages; percentages overlap because trials can be both oncology and rare disease.)
Offices, labs & site footprint: 20 offices and 2,350 experts across the Americas (US vs ex-US split not detailed) (Regional Americas footprint; Precision Site Network provides academic medical center access.)
Veristat
Phase claim: complex Phase I-III clinical development (Vendor service claim.)
Therapeutic focus: rare disease trial delivery and complex specialty programs (Vendor lists rare disease and natural history trial delivery; other indications not enumerated on page.)
Offices, labs & site footprint: Office/site footprint not quantified on reviewed page
Indero
Phase claim: early and late phase clinical trials (Vendor capability claim (formerly Innovaderm).)
Therapeutic focus: dual-focus dermatology (30+ indications) and rheumatology (20+ indications) (Specialty dual-focus CRO; North America CRU operates as Innovaderm.)
Offices, labs & site footprint: Office/site footprint not quantified on reviewed page
Kapadi
Phase claim: Not stated on reviewed page
Therapeutic focus: oncology (solid and liquid malignancies, immuno-oncology) and cell & gene therapies (common and rare indications) (Vendor specialty positioning; notes partnership/historic connection to Moffitt Cancer Center.)
Offices, labs & site footprint: Raleigh, North Carolina US registered office; North America specialty oncology site network (US registered office and North American network claim.)
PharPoint
Phase claim: Phase II-IV clinical trials (Vendor service page claim.)
Therapeutic focus: Not enumerated on reviewed page
Offices, labs & site footprint: Durham, NC and Wilmington, NC offices; experience working with locations across the United States (US offices and stated US location experience.)
Proxima CRO
Phase claim: Not stated on reviewed page
Therapeutic focus: Not enumerated on reviewed page
Offices, labs & site footprint: Houston, Texas US office (US office address; trial site footprint not detailed on homepage.)